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Abstract 
 
Background: Several studies report that patients who use serotonin reuptake 
inhibitors (SRIs) to treat depression may have increased risk of bleeding, particularly 
from the gastrointestinal tract. This may be related to low concentrations of serotonin 
in platelets. Several blood banks defer SRI users from platelet donation. Search in 
Medline have not revealed any study clarifying the effect of SRIs on platelets stored 
for transfusion. 
 
Methods: We conducted a prospective blinded randomized control study in blood 
donors using SRI (n=8) and in donors without medication (n=10). The test group 
consisted of 4 men and 4 women, and the median age was 40 years (range: 29-54 
years). The control group consisted of 3 women and 7 men, and the median age was 
39 years (range: 21-54 years). Platelet function was compared in whole blood and in 
platelet concentrates stored for up to five days. In addition, quantitative analyses of 
serotonin, tryptophan and tryptophan metabolites were undertaken.  
 
Results: Light transmission aggregometry, trombelastography and flow cytometric 
analysis of glycoprotein expression did not detected altered platelet function in blood 
donors using SRI. Routine tests for platelet confirmed high quality of platelet 
concentrate obtained from donors using SRIs. Blood donors using SRI have markedly 
lower platelet serotonin compared to blood donors without medication. 
 
Conclusion: The results from our pilot study indicate that patients using SRIs do not 
have altered platelet function and can be accepted as platelet donors. Our results are 
limited to platelets stored for 5 days and for low doses of SRI. There is a need for 
larger studies to finally clarify the influence of SRI on platelets stored transfusion. 
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Abbreviations 
 
ADP  Adenosin diphosphate 
BBB Blood brain barrier 
CD Cluster of differentiation 
CNS Central nervous system 
CYP Cytochrom P450 
DDD  Defined daily doses 
DTT Dithiothreitol  
DNA  Deoxyribonucleic acid 
DTS Dense tubular system 
EDTA Ethylenediaminetetraacetic acid 
FSC Forward scatter 
GIT Gastrointestinal tract 
GP Glycoprotein 
HPLC High performance liquid chromatography 
LTA Light transmission aggregometry 
LC-ESI-MS/MS Liquid chromatography- electronspray ionization- tandem mass 
spectrometry 
MAO Monoamin oxidase 
MP Microparticle 
NAD Nicotinamide adenin dinucleotide 
NADP Nicotinamide adenin dinucleotide phosphate 
NET Norepinephrine transporter 
NSAID Non-steroidal anti-inflammatory drug 
OCS Open canalicular system 
PAS Platelet additive solution 
pCO2 Partial pressure CO2 
PC Platelet concentrate 
PLT Platelet count 
pO2 Partial pressure O2 
PRP Platelet- rich plasma 
PPP Platelet- poor plasma 
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SDC Single donor concentrate 
SERT Serotonin transporter 
SNRI Serotonin norepinephrine reuptake inhibitor 
SRI Serotonin reuptake inhibitor 
SSRI Selective serotonin reuptake inhibitor 
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TCA Tricyclic antidepressant 
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TRAP Thrombin receptor activator peptide 
TXA2 Thromboxane A2 
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1 Introduction  
1.1 Background 
The Word Health Organization predicts that depression will become the leading 
contributor to disease burden in the western world within 2030 (1). The main 
biochemical theory of depression is the monoamine hypothesis, which claims that 
depression is caused by functionally deficient monoamergic transmission in the 
central nervous system (CNS) (2). The restoration of serotonin and norepinephrine 
deficiencies to normal levels as a therapeutic strategy is based on this hypothesis 
(3). In moderate and severe depression, pharmacological intervention is one of the 
main forms of effective treatment and the selective serotonin reuptake inhibitors 
(SSRIs) have dominated the antidepressant marked since the introduction in the 
1990 (4). More recently, the serotonin norepinephrie reuptake inhibitors (SNRIs) 
have been introduced as an alternative to the SSRIs. Serotonin reuptake inhibitor 
(SRI) is used as generic name for SSRI and SNRI.   
 
It is presumed that the mechanism of action of the SRIs is presynaptic blockade of 
the neuronal reuptake of norepinephrine and/or serotonin in the central nervous 
system, resulting in an increase in transmission by monoamine neurons (5, 6). In 
the last few years, numerous case reports and population-based cohort studies 
suggested that antidepressant with a relevant blockade action on the serotonin 
reuptake increase the risk of bleeding episodes, particularly from the 
gastrointestinal tract (GIT) (7-11). Studies indicate that patients using SSRI have 
increased transfusion requirements during orthopedic surgery have also been 
published (12, 13). In addition to serving as a neurotransmitter in the CNS, 
serotonin is involved in a variety of biological processes, including haemostasis. 
In humans, platelets are unable to synthesize serotonin, but almost all circulating 
serotonin is transported into platelet dense granules (14). Upon activation, 
platelets release serotonin, which acts as a vasoconstrictor and an amplifier of the 
aggregation response (15, 16). Currently, it is well established that platelets and 
neurons act similarly with respect to serotonin uptake, release and metabolism, 
and human platelets have been used as models for the study of several aspects 
regarding the function of CNS serotonergic neurons (17). Because serotonin 
promotes platelet aggregation, the underlying mechanism of impaired haemostasis 
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in patients using SRIs is suggested to be due to the depletion of serotonin in 
platelet as a result of the reuptake inhibition (18-20). 
 
The purpose of platelet transfusion is to provide platelets with satisfying 
haemostatic properties to patients suffering from thrombocytopenia or impaired 
platelet function. Blood donors are recruited among voluntary, healthy 
individuals. Accordingly, the main principle is that blood donors should be drug-
free. However, as the numbers of blood donors is below the need to ensure the 
blood supply, compromises must be made. Currently, there is word-wide 
agreement that blood donors needing substitution for hypothyreosis and woman 
using anticonseption therapy are eligible for donation. When it comes to drugs 
against depression, there is different practice between countries. In Norway, 
individuals using antidepressant drugs may be donors, which is not the case in 
Denmark (21). Search in Medline database, has not revealed any study clarifying 
the effect of SRIs on platelets stored for transfusion. We therefore conducted a 
prospective blinded randomized control study, aiming to compare platelet 
function in platelet concentrate (PC) during storage obtained from blood donors 
using SRIs as only medication and blood donors without medication. Additional 
in vitro platelet aggregation studies at baseline (day of donation) and quantitative 
analyses of serotonin and the serotonin precursor tryptophan were also performed.  
1.2 Platelets  
Platelets are small, irregularly shaped fragments derived from the cytoplasm of 
the megakaryocyte. After passage from the bone marrow into the bloodstream, the 
platelets circulate for less than 10 days before ending their short life in the spleen.  
The platelets normally range from 2 to 4 µm in diameters, and they only contain 
mitochondrial DNA since they lack a nucleus (22). The platelet concentration in 
healthy individuals varies between 250,000 and 400,00 platelets per µl of blood 
and the major biological role of the platelets is the maintenance of the haemostasis 
by sealing rifts in the vascular tree (22). 
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1.2.1 Morphology 
      
      Organelles 
Platelets contain organelles that are essential for normal platelet function. The 
mitochondria are responsible for oxidative metabolism, which supplies energy. 
Peroxisomes are small organelles presents in platelets, assumed to play an 
important role in the lipid metabolism. Platelets also possess three types of 
granules. α- granules are the most abundant granules in the platelets and contain 
factors, which are released upon activation to facilitate vessel repair, platelet 
aggregation and coagulation of blood (23). The dense bodies are another type of 
granules, which contain factors facilitating platelet aggregation and adhesion as 
well as factors able to induce vasoconstriction (24). The third types of granules 
are the lysosomes, which contain hydrolytic enzymes.  
 
      Cytoskeleton 
The platelet cytoskeleton consists of three main components. The microtubuli coil 
and the membrane skeleton are situated immediately below the plasma membrane, 
while a network of long- interconnecting actin filaments fill the cytoplasm (25). 
The dynamic behaviour of the cytoskeleton is responsible for the rapid change in 
shape upon activation of platelets. The cytoskeleton also regulates activities of 
membrane proteins, and binds signal molecules, directing them to specific cellular 
location (25). 
 
Tubular systems 
The surface-connected open canalicular system (OCS) is a unique feature of the 
platelet anatomy. It consists of a series of conduits that begin as indentations of 
the plasma membrane and permeate the interior of the platelet. The OCS provides 
a way for the platelets to communicate with the outside by allowing entry of 
external elements and by providing a “road system” for the release of the granule 
contents in addition to function as a storage compartments for glycoproteins (26). 
The platelets also possess another tubular system called the dense tubular system 
(DTS). The dense tubular system is a closed channel network, originating from 
the endoplasmatic reticulum of the megacaryocyte. The membrane system 
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functions to release calcium, regulating platelet activation (27). It is probably also 
a major site of prostaglandin and tromboxane synthesis (28). 
 
The plasma membrane 
The plasma membrane consists of a bilayer of phospholipids in which cholesterol, 
glycolipids and glycoproteins are embedded. In activated platelets the distribution 
of phospholipids is asymmetric, giving rise to a negatively charged membrane 
inside (29). The negatively charged phospholipids serve as a catalytic surface, 
which is able to accelerate several steps in the coagulation sequence (29). 
Numerous glycoproteins are present on the platelet surface, which facilitate 
interactions with subendothelial structure, blood cells or other platelets.  
 
Platelet surface molecules 
Many molecules cover the platelet surface. The molecules that are most important 
for platelet function and the molecules that we used to measure platelet activation 
in this study, are addressed here. For didactic reasons they are separated into two 
groups; receptors and activation markers.  
 
Platelet receptors 
When the corresponding ligand binds to a receptor, a well defined response is 
performed. The receptors relevant for this study are summarized in Table 1.1. 
 
Table 1.1 Agonists, ligands and receptors important for platelet function  
Function Receptors Ligand/Agonist 
GPIb/V/IX vWF 
Adhesion 
GPIa/IIa Collagen 
PAR-1 Thrombin 
P2Y1, P2Y12 ADP 
5-HT2A Serotonin 
TPαβ, TPβ TXA2 
Activation and 
amplification 
α2A Epinephrine 
Aggregation Activated GPIIb/IIIa Fibrinogen 
TXA2= tromboxane A2 
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Following vascular injuries, the endothelium release von Willebrand factor 
(vWF), which deposits in the area of damage. The multiple binding sites of vWF, 
enable binding to platelet receptor GPIb/IX/V and the major matrix protein 
collagen, resulting in platelets capture at site of injury. ADP released from the 
dense bodies mediates mobilization of Ca2+, shape change, transient aggregation 
and platelet secretion predominantly via two important ADP receptors on the 
platelet surface (30). Serotonin binds to the G-protein-coupled 5-HT2A and 
amplifies together with ADP the platelet response. TXA2 mediates platelet 
aggregation and shape change via two distinct platelets receptors (31), while 
epinephrine synergize with others agonist like ADP. Thrombin is one of the most 
potent platelet agonists and activates the G-protein-coupled receptor PAR-1 (32). 
The platelet receptor GPIIb/IIIa, also termed CD61, plays a key role in platelet 
aggregation. GPIIb/IIIA is present at high density on the platelet surface, but in a 
low-affinity ligand-binding state on resting platelets. Activation by agonists 
including ADP, serotonin, thrombin and collagen causes conformation change and 
promotes the binding to fibrinogen (33). 
 
Platelet activation markers 
GPIbα, also termed CD42b, is a subunit of the GPIb complex, which constitutes 
the binding site for vWF (34). Decreased expression of CD42b is shown to be a 
reliable marker for platelet activation (35). P-selectin, also termed CD62P, is a 
glycoprotein present in the membrane of α granules in resting platelets. Upon 
platelet activation, the protein is secreted and expressed on the platelet surface 
(36) to mediate the attachment of neurophiles and monocytes to platelets and 
endothelial cells (37). Increased expression of P-selectin is widely used as a 
marker of platelet activation (38, 39).   
1.2.2 Platelet Function 
Hemostasis is a complex physiological process, which prevents extensive 
bleeding after vessel wall injury and ensuring viable coagulation by keeping the 
blood in an uncoaculated state.  The process of stopping a bleeding by sealing rifts 
in the vascular tree requires the combined activity of platelets, plasma factors and 
blood vessels. For didactic reasons, haemostasis is usually divided into primary 
and secondary haemostasis.  
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Primary hemostasis 
The first response after injury of small blood vessels is the process of arteriolar 
vasoconstriction to reduce local blood flow. Vasoconstriction not only reduces 
extensive blood loss, but it also promotes the adherence of platelets to exposed 
subendothelial material. For this to occur, platelets must undergo activation by 
physiology platelet agonists. These activators are present at the site of vascular 
injury, giving a local response. Based on their ability to induce platelet activation, 
agonist can be classified as either weak (e.g., epinephrine, serotonin, ADP) or 
strong (e.g. collagen and high-dose thrombin). Platelet activation results in several 
phenomena:  
 
1. Adhesion 
Platelet adhesion is the initial step in the formation of a platelet plug.  
vWF-dependent adhesion occurs predominantly at medium and high shear rates 
conditions as found in small arteries and arterioles, probably because high shear 
rates cause conformational change in vWF and/or platelets GPIb (40) . Under 
static or low shear conditions, platelets may also adhere directly to collagen 
through the platelet collagen receptors GPIa/IIa and GPVI (41). 
 
2. Shape change 
Upon activation by agonists and exposure to collagen, disk- shaped platelets turn 
into spheres with extensive formation of pseudopodia originating from the plasma 
membrane. The response originates from a change in the assembly of the 
cytoskeleton, and is fast and energy requiring (42). The presence of the swirling 
phenomenon correlates with the platelets discoid shape, and it disappears when 
platelets become spherical (43).  
 
3. Secretion 
Interactions between platelets and vascular cells are modulated by granular 
components released from activated platelets. ADP is considered an essential 
physiological agonist as it contributes significantly to the full aggregation 
response induced by other platelet activation markers like serotonin (44). 
Adhesive glycoproteins, coagulation factors, plasma protein e.g. released from the 
α-granules, facilitate vessel repair, platelets aggregation and coagulation of blood.  
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4. Aggregation 
The platelet aggregation is characterized by the formation a hemostatic plug. 
Activated GPIIb/IIIa receptors on adherent platelets results in the recruitment of 
additional layers of platelet via cross-linking activated platelets through fibrinogen 
bridges. 
 
Secondary haemostasis 
The hemostatic plug is friable and must be stabilized by fibrin to avoid being 
washed away when the vasoconstriction reverses. The classical model of 
coagulation describes a sequentially conversion of pro-enzyme to enzyme, along 
either an intrinsic or extrinsic pathway. Activation of any of these two pathways 
leads to the formation of thrombin and subsequently fibrin. The absence of 
platelets and the separation into two pathways has made the coagulation cascade 
theory inadequate for the explanation of hemostasis in vivo. The cell-based model 
of hemostasis presented by Hoffmann et al. has been accepted as a more accurate 
explanation of in vivo hemostasis (45). In this model, coagulation occurs not as a 
cascade but in three overlapping stages: Initiation, amplification and propagation. 
 
1. Initiation 
Initiation of coagulation is triggered by tissue factor (TF), which is an integral 
membrane protein expressed by cells generally found outside the vasculature. 
Once an injury occurs in the vessel wall, TF will be exposed. Coagulation factor 
VII is activated and binds to TF. The TF-FVIIa complex is capable of activating 
both FIX and FX, and FXa can further activate FV. A FXa/Va complex on the 
surface of the TF-bearing cells converts small amounts of prothrombin to 
thrombin, which diffuse away from the surface of TF-bearing cells and act on 
platelets close to the site of injury. Initiation is summarised in Figure 1.1 B.  
 
2. Amplification 
At this stage, the process moves from the TF-bearing cell to the platelet surface. 
The small amount of thrombin generated on the TF-bearing cells amplifies the 
initial procoagulant signal by activating platelets that have leaked from the 
vasculature at the site of injury. In addition, thrombin activates FXI and FV on 
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platelet surface, and cleaves of FVIII from vWF. Amplification is summarised in 
Figure 1.1 B.  
 
3. Propagation 
During the propagation phase, FIXa binds to FVIIa on the platelet surface, which 
also causes further generating of FXa. The FXa/FVa complex generates a burst of 
thrombin, which removes fibrinpeptides from fibrinogen to form fibrin monomers. 
The fibrin monomers polymerize spontaneous for form an insoluble gel, which is 
stabilized by FIIIa. The fibrin aggregate and the platelets act together to stop 
further bleeding. The propagation is summarised in Figure 1.1 C.  
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Figure 1.1. The cell-based model of fibrin formation composes three overlapping phases. A) 
Initiation Phase: TF- bearing cell activate a FX/V complex and the overall outcome is the 
generation of small amounts of thrombin, which diffuse away from the surface of TF-bearing 
cells to platelets. B) Amplification phase: The small amount of thrombin generated during 
initiation activates platelets and FV, FXI and FVIII. C) Propagation phase: Formation of a 
FX/V and FIX/VIII complex on activated platelet surface leads to a burst of thrombin 
generation. The figure is adapted by Hoffman, 2003 (46). 
  
1.2.3 Platelet-derived microparticles 
Microparticles (MP) are circulating membrane vesicles derived from platelets 
(47). They contain cytoplasmic components and possess membrane receptors 
inherited from their parental cell. Platelet microparticles are released from 
activated platelets and defined as vesicles less than 1 µm in diameter (48). MPs 
support procoagulant activity and contribute to formation of the hemostatic plug 
(49).  
1.3    Tryptophan  
Tryptophan is one of the eight essential amino acids, and both excessive intake 
and deficiency of tryptophan are detrimental to health. As in the case for all other 
amino acid, only the L isomer is used in protein synthesis (50). It is believed that 
tryptophan can play a rate-limiting role in protein synthesis, possibly because 
tryptophan is the amino acid with the lowest overall concentration in the body 
(51). 
 
In addition to the principal role as a constituent of protein synthesis, tryptophan is 
involved in different metabolic pathways. Approximately 90 % of the tryptophan 
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catabolism results in the formation of kynureinine, which is a key component in 
the synthesis of a range of biologically active compounds (51). Its most important 
metabolites include kynurenic acid, which is a glutamate receptor antagonist, and 
quinolinic acid, which is a glutamate receptor agonist (52).  Kynurenine may 
ultimately be converted to the coenzymes nicotamide adenine dinucleotide (NAD) 
and NAD phosphate (NADP), which are essential for electron transfer reactions in 
living cell (51). A large fraction of the body’s NAD and NADP may be formed 
from tryptophan, while remainder is obtained from the diet (53). Persons who 
consume a diet that is low in tryptophan may develop deficiency of these 
coenzymes, a condition that is known as pellagra and may be associated with high 
morbidity and mortality. Less then 5 % of dietary tryptophan is used for serotonin 
synthesis (54), despite the fact that serotonin has wide-ranging effects throughout 
the body. Melatonin, which is known for its role in regulating diurnal rhythms in 
synthesised from serotonin in the pineal gland (51).  
 
Thus, the kynurenine and serotonin pathways are interconnected and their 
integrity depends upon the availability of adequate amounts of tryptophan. This 
may be a problem in patients with carcinoids, which are neuroendocrine tumors 
usually present in the gut. A large tumor may produce substantial amounts of 
serotonin, and this may deplete body stores of tryptophan and cause pellagra like 
symptoms because of low levels of NAD and NADP (55).  
1.4      Serotonin 
In the late 1940s, Rapport et al discovered a unknown substance in the serum after 
blood had clotted (56). The substance was identified as a vasoconstrictor 
substance and the chemical name 5-hydroxytryptamine (5-HT) was given.  
1.4.1 Biosynthesis, storage and metabolism 
Serotonin is synthesised from the dietary amino acid tryptophan and the pathway 
involves two enzymatic steps. First, L-tryptophan is hydroxylated to 5-hydroxy-
tryptophan (5-HTP) by the action of tryptophan hydroxylase. In the second step 5-
HTP is decarboxylated to form 5-HT by L-amino acid decarboxylase. While both 
enzymes are necessary for the conversion of tryptophan to serotonin, the first step 
is considered the rate limited step (57).  
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About 95 % of all human serotonin is located outside CNS and the 
enterochromaffin cells in the GIT are almost entirely responsible for the synthesis 
of all peripheral serotonin (58). The gut is also a major storage site for serotonin. 
Unlike the enterochromafinn cells, platelets lack the enzymes to synthesize 
serotonin. Instead, serotonin released into the circulation from the 
enterochromafinn cells is rapidly taken up by platelets and stored in platelets 
dense granules, leaving a very small fraction freely circulating (14). Only a small 
fraction of the total body serotonin is synthesised in the CNS. Because the blood-
brain-barrier (BBB) is impermeable to serotonin, the amount of serotonin 
produced centrally is dependent on the amount of tryptophan available to cross 
BBB by the action of a non-specific carrier protein (59, 60). Monoamine oxidase 
(MAO) and aldehyd dehydrogenase is responsible for degradation of serotonin 
respectively through oxidative deamination and oxidation to form 5-
hydroxyindoleacetic acid (5-HIAA). Circulating serotonin is mainly metabolized 
in the liver, except a small amount, which is degraded in the endothelium of lung 
capillaries. 5-HIAA in the brain is transported to the peripheral where it is 
excreted in the urine along with peripheral 5-HIAA (57). Figure 1.2 summarizes 
the life cycle of serotonin. 
 
          
 
Figure 1.2: The synthesis, release, reuptake and metabolism of serotonin in a serotonergic 
neuronal synapse. Adapted from Ni et al., 2003 (61) 
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1.4.2 Serotonin receptors 
The diverse effect of serotonin is mediated via 5-HT receptors, localized both in 
the central and peripheral nervous system, as well as in a number of nonneural 
tissues including the gut, blood and the cardiovascular system. Currently, there are 
15 known serotonin receptor subtypes, divided into seven families (5-HT1-7) based 
on their structure, pharmacology and transduction signal (62). With the exception 
of 5-HT3, which is a ligand-gated ion channel, 5-HT receptors belong to the 
family of G-protein- coupled receptors (62). The earlier discovered 5-HT1, 5-HT2, 
5-HT3 and 5-HT4 have been subjects to extensive research, and are consequently 
best understood of all the serotonin receptors.  
1.4.3 Serotonin transport 
Serotonin transporter (SERT) is a plasma membrane protein that selectively 
transports serotonin back into the cell cytoplasm for metabolism or vesicular 
repackaging. SERT possesses twelve transmembrane domains, and represents the 
first step in the action of terminating serotonin at its extracelluar cognate 
receptors. The serotonin transporter belongs to a family of Na+/Cl- dependent 
transporter that include transporter for norepinephrine, dompamin, glycine and 
GABA (61). Serotonin together with Na+ and Cl- are transported in the same 
direction, whereas K+ ions are transported out of the cell. SERT is the drug target 
for the SRIs, but also other psychostimulant drugs like cocaine and amphetamine 
(63).  
 
 
Figure NN: The serotonin transporter (SERT) is a sodium chloride-dependent 
neurotransmitter symporter. SERT removes serotonin from extracelluar space by high 
affinitet reuptake into cells. The figure is adapted from: NI et al. 2006 (61) 
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1.4.4 Serotonin physiology 
Currently, we now that serotonin plays an important role in a variety of biological 
processes, and the profusion of 5-HT receptors reflects the complex mechanism of 
action of serotonin.  
 
Serotonin and the CNS 
In the CNS, serotonin is almost exclusively synthesized in neurons originating in 
the raphe nuclei, a cluster of nuclei found in the brain stem (64). In human brain, 
these neurons possess the largest and most complex efferent system we know, and 
it is assumed that virtually all brain regions express multiple serotonin receptors. 
Serotonin is believed to play an important role in almost all brain regulated 
activities ranging from temperature regulation, appetite, sleep cycles and emesis 
among others (65). The most clinical aspect has been the role of serotonin in 
human behaviour disorders. Currently, serotonin is believed to be involved in 
psychiatric disorders like depression, anxiety, obsessive-compulsive disorders and 
eating disorders (66, 67).  
 
Serotonin and the gastrointestinal tract 
A variety of different neurotransmitters have shown to interfere with 
gastrointestinal motor and sensory functions, including serotonin. Low pH, 
acetylcholine, sympathetic nerve stimulation and elevated intraluminal pressure, 
all contribute to the release of serotonin from the enterochromaffin cells in the 
gastrointestinal tract (68). Serotonin regulates digestion by initiating peristaltic 
and secretory reflexes (69). Currently, there is increasing evidence that serotonin 
contribute to the pathophysiology of gastrointestinal disorders such as 
inflammatory bowel disease and irritable bowel syndrome (70, 71).  
 
Serotonin and the cardiovascular system 
The effects of serotonin on the cardiovascular system are numerous and complex. 
Serotonin mediates its central neurotransmitter effect on the cardiovascular system 
by activating sympathetic and parasympathetic pathways (72, 73). Serotonin 
receptors are also represented on vascular smooth muscle cells and endothelial 
cells, causing either vasocontriction or vasodilation dependent on the receptor 
expressed (74).  
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Serotonin and platelets 
Platelets lack the enzymes to synthesize serotonin, but have an extensive capacity 
to actively take up serotonin into dense granule from plasma (14). Upon 
activation, the release of serotonin from platelets is believed to cause multiple 
responses even though serotonin is classified as a weak platelet agonist.  The 
receptor that mediates serotonin’s effect on platelet function has been 
pharmacologically classified as the 5HT2-receptor (75). Serotonin is not assumed 
to cause platelet aggregation itself, but it enhances aggregation induced by ADP 
(16). In addition, serotonin causes vasoconstriction of blood vessels that have 
suffered endothelial damage by the interaction with 5HT2-receptor in the vessel 
wall (15). Serotonin can also promote the release of nitrix oxide from endothelial 
cells, which brings out a relaxing response on the vessel walls (57).  
 
However, recent studies have expanded the classical paradigm, in which serotonin 
mediates its action by the interaction with membrane bound receptors. It has been 
postulated that intracellular serotonin can facilitate platelet alpha granule release 
by activating G-protein-dependent signalling pathways (76). In addition, the 
revealing that serotonin is covalently cross-linked to a variety of adhesion proteins 
and clotting factors on the platelet cell surface (77) have given rise to many new 
questions concerning the role of serotonin in hemostasis, as well in other organ 
systems. 
 
Endogenous serotonin content has also been linked to platelet function during 
storage. Earlier studies from our group has reported that reduced intra-platelet 
serotonin content is related to impaired platelet function (78). 
1.5    Antidepressant drugs 
Depression is a common psychiatric condition worldwide, characterised with a 
persistent and substantial functional impairment. A variety of biochemical 
theories have arisen to explain the mechanism of depression, and a corresponding 
variety of different drug have been used in treatment. Functional deficiencies of 
serotonin and norepinephrine in synaptic regions have become the leading theory 
regarding the patophysiology of depressive symptoms (3), and drugs that 
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selectively inhibit the reuptake of the central monoamines have shown to be 
effective in treating symptoms associated with depressive illnesses (79). 
Defined daily doses (DDD) is the assumed average maintenance dose per day for 
a drug used for its main indication in adults (80). The consumption of some of the 
frequently prescribed class of antidepressant in Norway in 2009 is given in Table 
1.2. The numbers are from the Norwegian prescription database (81). 
 
Table 1.2: Antidepressant drug consumption in Norway in 2009  
Antidepressant class DDDs/1000 inhabitants/year 
TCA 3.46 
SSRI 34.56 
SNRI 6.67 
TCA= tricyclic antidepressant 
1.5.1 Selective serotonin reuptake inhibitor 
SSRI were developed as a result of the need for less CNS-toxic and cardiotoxic 
drugs than TCA. Despite the improvement in side effect profiles, the SSRI are 
generally not considered more clinically efficacious at treating depression than 
any previous antidepressant drugs (82). They are, however, considered as first-line 
drug of choice for treating moderate to severe depression due to the fact that SSRI 
are better tolerated and are safer in overdose than other classes of antidepressants.  
 
As the name implies, SSRIs interfere with the neurotransmitter serotonin in the 
CNS. By blocking the reuptake of serotonin into the presynaptic cell by inhibiting 
SERT, the concentration of serotonin in the synaptic cleft is increased. This means 
that activation of the serotonin receptors can take place to a much greater extent. 
The antidepressant effect is related to secondary adaptive changes in the CNS and 
altered expression of membrane receptors and emerges after 2-4 weeks (5). As 
well as being used by patient with depression, SSRI have also shown to be 
effective in treating patient with anxiety disorders, panic attack and obsessive-
compulsive disorder (83-85). In Norway, six different SSRIs are available, and 
they are considering to be equally concerning antidepressiv effect and side effect 
profile (86, 87). They differ, however, in their pharmacokinetic properties as seen 
in Table 1.2. 
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Table 1.2: Pharmacokinetic parameters of SSRIs 
Drug Daily dose (mg) 
DV 
(kg/L) t1/2  
Active 
metabolite 
CYP 
inhibition 
Fluoxetine 20-80 20-45 4-6 days Yes 2D6 
Fluvoxamine 50-300 25 15-22 hours Yes 1A2, 2C19 
Paroxetine 20-50 3-12 24 hours No 2D6 
Sertraline 50-200 20 22-36 hours Yes 2D6 
Citalopram 10-60 12-14 24-48 hours Yes Minimal 
Escitalopram 10-20 12-26 27-32 hours Yes Minimal 
DV = distribution volume, t1/2 = half life 
 
Fluoxetine differ most from the other SSRIs due to its long half-life and due to its 
highly biologically active metabolite, norfluoxetine (88). Because of this, 
fluoxetine appears to have a slower onset of action than other SSRIs. However, 
the long-half life may be beneficial for patients who have experienced severe 
withdrawal symptoms in the past. Fluoxetine also differ from the other SSRIs 
because of its high distribution volume (89, 90).  
 
All SSRIs are highly lipohilic and undergoes extensive hepatic metabolism, which 
involves the human CYP system. The effect of SSRI on specific CYP isoforms 
has been one of the major distinguishing factors among this class of 
antidepressants. Fluoxetine and paroxetine are potent inhibitors of CYP2D6, 
which can lead to increased plasma concentrations of coadministered drugs 
metabolised by this enzymes like certain TCA and antipsychotics (89). Because of 
long half-life of fluoxetine and norfluoxetine, potential CYP inhibiton and drug-
drug interactions may occur even weeks after discontinuation of fluoxetine. 
Fluvoxamine markedly inhibit CYP1A2 and CYP2C19, and have been reported to 
impair the elimination of certain TCA and various neuroleptics with clinical 
implications (91). Citalopram and escitalopram have weak inhibitory effect on 
various CYP isoforms in vitro and appear to have more favourable drug-
interactions profile in vivo compared to the others SSRI (91).  
1.5.2 Serotonin- norepinephrine reuptake inhibitors  
In the recent years, there has been an increased interest in antidepressants with 
broader mechanism of action due to failure of SSRIs to treat subgroups of 
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depressed patients. The antidepressant activity of SNRIs is based on the inhibition 
of SERT and the norepinephrine transporter (NET). It has been suggested that this 
dual-action antidepressant group may increase clinical utility in severe depression 
compared to the SSRIs (92). Two different SNRIs are available on the Norwegian 
marked, venlafaxine and duloxetine. As seen in table 1.3 they possess different 
pharmacokinetic (88, 91, 93, 94).  
 
Table 1.3 Pharmacokinetic parameters of SNRIs 
Drug Daily dose (mg) dV (kg/L) 
t1/2 
(hours) 
Active 
metabolite CYP inhibiton  
Venlafaxine 75-375 3.8- 11.2  ∼ 5  Yes Minimal  
Duloxetine 60-120 11-50 8-17  No CYP 2D6 
DV = distribution volume, t1/2 = half life 
 
Venlafaxine 
Venlafaxine was the first marketed antidepressant in the SNRI class. It is a potent 
selective serotonin reuptake inhibitor at lower doses as venlafaxine has a 30-fold 
higher affinity to SERT than NET (95). By increasing the daily dose to >150 mg, 
venlafaxine exert dual antidepressant effect because its noradrenic effect becomes 
more apparent (95). Earlier reviews of the safety of venlafaxine has, suggested 
that there is an increased risk of cardiac events associated with venlafaxine 
compared to SSRIs (96, 97). A newly published nested case-control study have, 
however, questioned this association (98).  
 
Duloxetine 
Duloxetine is a relatively new antidepressant in the SNRI class. It has high 
affinity for both SERT and NET in contrast to venlafaxine (99). As well as being 
effective in the treatment of emotional/physcological symptoms associated with 
depression, duloxetine has shown to be effective in treating pain in general and 
painful physical symptoms in depression (100). It is suggested that this additional 
effect gives rise to better response rates and remission from depressive symptoms 
compared to SSRI. In Norway, duloxetine is also licensed for treating diabetic 
naturopathic pain and stress urinary incontinence in woman.    
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1.6   Transfusion Medicine 
Modern transfusion practice is based on the use of blood components produced 
from whole blood donations or apheresis procedures. The use of blood 
components rather than whole blood has the advantageous of more effective 
utilization of blood donations, optimal preservation of blood components in vitro 
and more effective treatment by specific replacement of deficiency. National 
regulations and international guidelines ensure high quality and safety of all 
procedures related to all fields of transfusion medicine (101, 102). The bloods 
banks must ensure that individuals fulfil certain criteria before being accepted as 
blood donors, and that they give their informed written consent before donation. 
Testing for HIV, hepatitis B and C must be performed at every donation, and the 
national blood banks must have a system for reporting the outcome of every 
transfusion.  
1.6.1 Preparation of platelet concentrate 
Platelet collection follows one of two alternatives, preparation of whole blood or 
platelet apheresis. Whole blood-derived platelet concentrate can be prepared from 
either buffy-coat or from platelet-rich plasma. It is required 4- 6 donations to 
obtain a standard dose of platelets (102). Platelet apheresis techniques enable the 
blood bank to collect up to 12 times the platelet dose that can be recovered from 
one whole blood donation, giving the advantage of exposing the patient to fewer 
donors. This reduces the risk for immunisation as the recipient is exposed to less 
antigen stimulation (103). The platelets are stored either in plasma or in a 
combination of plasma and additive solution. Many drugs like aspirin and non-
steroidal anti-inflammatory drug (NSAIDs) are known to impair platelet functions 
and it is therefore crucial to ensure that the blood donors have not ingested such 
drugs during the last five days before donation.  
1.6.2 Platelet additive solution 
Platelet additive solution (PAS) is used as a substitute for plasma in order to make 
plasma available for other needs and reduce the risk of possible circulatory 
overload following transfusion of larger volume. 70-80 % of the plasma is 
replaced with PAS, giving the additional benefits of reduced allergic and febrile 
transfusion reactions (104) and decreased transfusion of unwanted antibodies 
since these side effects are related to plasma content (105).  In addition, the use of 
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synthetic medium makes it possible to include components that support good 
platelet function. Several platelets additive solutions with different composition 
are currently available. Most additive solutions use acetate as metabolic fuel for 
the platelets, which also has the benefit of generating buffer capacity. 
Alternatively, glucose can be used. Adding another buffering substance like 
phosphate to maintain a neutral pH is possible. Citrate is added as an 
anticoagulant. The latest generation of additive solutions often contains 
magnesium and potassium, which have shown to limit platelet activation and 
therefore reducing the platelet storage lesion (106). 
 
4.5.3   Storage of platelets 
Platelets are stored with continuous agitation and the temperature should be 
+20°C to + 24°C (102). Because of bacterial contamination and storage-related 
deterioration, the platelet storage time is limited to 5 days. If platelet bacterial 
testing is performed, the storage period can be extended to 7 days (102).  Platelets 
are particularly sensitive to storage conditions, and numerous morphologic, 
biochemical and functional derangements demonstrate that platelets tend to 
become activated during storage. These include loss of disc shape (43), increased 
surface glycoprotein expression (107) and increases release of platelet α-granules 
(108). All of these findings have proven to demonstrate platelet activation (43, 
109). The phenomenon concerning changes in platelet structure and function 
arising during storage is generally referred to as the platelet storage lesion. 
Conventional assays, like record of the swirling phenomenon, hypertonic shock 
response, pH, pO2 and pCO2 and mean platelet volume are used as quality markers 
to ensure the platelets integrity during storage. It is difficult to prove strong 
correlation between in vitro test results and in vivo platelet function. There is, 
however, good evidence suggesting that that many platelet storage abnormalities 
observed in vitro reverse during transfusion (109).  
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2 Subjects and materials 
2.1 Study participants  
This prospective blinded randomized control study was approved by the local 
Research Ethics Committee (University of Bergen, Norway). The subjects were 
recruited from the Blood Bank, Haukeland University Hospital. Blood donors who 
provided information on SRI and had adequate periphereal venous access and blood 
platelet concentration sufficient for undergoing platelet apheresis were asked to 
participate in the test group. Individuals fulfilling the same criteria, but not using any 
medications, were used as controls. Only subjects who gave written consent were 
included in the study. A total of 18 individuals were included in the study, whereas 8 
blood donors using SRI for at least one year were included in the test group. All 
donors met usual requirements for an acceptable donation, were healthy and had not 
taken any drugs influencing platelet function for at least 5 days prior to donation. The 
characteristics of the donors included in the study are given in Table 2.1 and 2.2. 
 
Table 2.1 Characteristics of the individuals in the test group 
Number 
Sex 
(M=Male) 
(F=Female) 
Age 
(yrs) Drug Dose 
1 F 54 Citalopram (Cipramil) 10mg x 1 
2 F 35 Paroksetin (Seroxat) 10mg x 1 
3 M 36 Escitalopram (Cipralex) 10mg x 1 
4 F 50 Escitalopram (Cipralex) 20mg x 1 
5 M 40 Venlafaxine (Efexor) 75mg x 1 
6 M 40 Venlafaxine(Efexor) 75mg x 3 
7 M 45 Venlafaxine (Efexor) 75mg x 2 
8 F 29 Escitalopram (Cipralex) 10mg x 1 
 
Table 2.2: Characteristics of the individuals included in the control group.  
Number 
Sex 
(M=Male) 
(F=Female) 
Age 
(yrs) Drug 
1 M 32 None 
2 M 54 None 
3 F 44 None 
4 M 29 None 
5 M 43 None 
6 M 42 None 
7 F 28 None 
8 F 35 None 
9 M 21 None 
10 M 50 None 
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The median age was 40 years (range: 29-54 years) in the test group and 39 years in 
the control group (range: 21-54 years). While there was an equal distribution of men 
and woman in the test group, three woman and seven men were included in the 
control group. 
2.2 Blood sample collection 
Single donor concentrates (SDC) were collected by single-needle apheresis 
employing the elutriation principle to provide leukocyte-reduced platelets (Fenwal 
Amicus Cell Separator, Baxter Healthcare Corp., Deerfield, IL, USA). During the 
apheresis procedure, whole blood is removed from the donor and anticoagulated with 
a citrate solution. Following centrifugation, the constitutes of the blood are separated 
and the platelets are collected. The remaining blood components are returned to the 
donor.  
 
Prior to the apheresis procedure whole blood from the donors was collected in a 
satellite bag and immediately transferred to three citrate tubes (4.5 ml 0.129M/3.8% 
Sodium Citrate, BD Vacutainer, BD bioscience, Plymouth, UK) and one EDTA tube 
(3 ml K3EDTA, Greiner Vacuette, Greiner Bio-One International AG, 
Kremsmuenster, Austria). Testing on day was completed within 2 hours of collection 
2.3 Sample preparation 
2.3.1 Citrated whole blood 
Citrated whole blood was obtained as described under blood sample collection in 
section 2.2.  
2.3.2 Platelet-rich plasma (PRP) and platelet-poor plasma (PPP) 
PRP was obtained by centrifugation (Heraeus labofuge A, Heraeus Sepatech, 
Germany) of 3.8% citrated whole blood for 15 min at 110 G. The PRP was transferred 
to a plastic tube, and the sample was then centrifuged for 10 min at 1740 x g to 
prepare PPP.    
2.3.3 EDTA plasma 
The EDTA vacutainer tube was immediately put on ice, before being centrifuged 
(Mikro 200R, Hettich Zentrifugen, Hettich, Kirchlengern, Germany) at 2000 x g and 
4°C for 10 min. The plasma was then obtained and stored at -80°C until use.  
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2.3.4 Platelet concentrate 
SDCs were stored in 37 % plasma and 63 % PAS (Intersol, Fenwal, Lake Zurich, IL, 
USA) in plastic bags under routine conditions at 22°C on a horizontal agitator 
(Helmer, Noblesville, IN, USA). A maximum of 4.5 ml platelet concentrate was 
removed from each SDC before performing a particular analysis.  
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3 Methods 
 
Tests of platelet function attempt to measure a defined event in the platelet activation 
process in an individual patient. A range of methods is available, making it possible to 
identify platelet dysfunction, monitor anti-platelet therapy and assessing the quality of 
stored platelets. In this study, we used following methods:  
3.1 Light transmission platelet aggregometry 
3.1.1 Principles of the method  
Light transmission platelet aggregometry (LTA) measures the change in light 
transmission as a result of in vitro platelet-to-platelet aggregation following addition 
of an agonist. Classical Born aggregometry measures light transmission through PRP 
relative to autologous PPP. A beam of infrared light is directed through the two 
samples and detected by a silicon photodiode. PPP is considered to give 100% light 
transmission, because all light passes through the sample. No light is able to pass 
PRP, and PRP is therefore defined to allow 0% light transmission. Addition of an 
agonist to the PRP leads to increasing transmittance of light as larger and larger 
aggregates form. The optical aggregation output is proportional to the continuously 
measured difference in transmission between PPP and PRP. A range of agonists with 
different concentration can be used in LTA, making it possible to obtain additional 
information if the platelets are exposed simultaneously to more that one activator or a 
combination of activators and inhibitors.   
The aggregation profile can be divided into two phases: 
1) Primary aggregation, which is characteristic with a reversible aggregation 
response. 
2) Secondary aggregation, which possesses an irreversible aggregation response.  
 
To evaluate the aggregation curve, Max aggregation and aggregation velocity 
expressed as change over time (%/min) are calculated. Max aggregation = 
aggregation amplitude, represents the change in light transmission from the addition 
of an agonist (baseline) to the highest point on the aggregation curve. This parameter 
can easily be obtained by reading directly of the chart at the end of the aggregation 
profile. Change in aggregation velocity over time is determined by drawing a tangent 
to the steepest part of the curve. The slope is calculated, and expressed as percentage 
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aggregation per minute (%/min).  Figure 3.1 shows how calculations of slope and max 
aggregation were done.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Calculation of max aggregation and slope. Max aggregation is obtained by reading 
directly of the chart at the highest point one the aggregation curve. The slope is calculated by 
constructing a triangle with a one minute base. The height is calculated and the value is 
represented as aggregation/minute (slope).     
3.1.2 Practical test procedure 
The LTA analysis was performed on day of donation on a Whole Blood Lumi-
Aggregometer (Chrono-log Corporation, Model 560-Ca, Havertown, PA, USA). Two 
cuvettes, one containing PRP (sample) and one containing PPP (reference), are placed 
in chambers, pre-varmed to 37°. 100 % baseline is established using PPP, and 0 % 
baseline is achieved by the use of PRP. The addition of 50 µl ADP (Sigma-Aldrich, 
St.Louise, MO, USA) to 450 µl PRP induces platelet aggregation. The PRP is stirred 
at 1000 rpm and allowed to run for a minimum of 5 minutes. Final concentration of 
agonists obtained in sample includes 5 µM ADP and 2 µM ADP. 
0 % Transmission (PRP) 
100 % transmission (PPP) 
73% 
1 min 
Maxagg=60 % 
Slope =73 %/min 
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3.2 Thrombelastography  
3.2.1 Principles of the method 
Thrombelastography (TEG) measures viscoelastic changes during coagulation of 
blood in vitro. In classical TEG analysis, whole blood is added to a cup and incubated 
at 37°C. If not immediate processing using native blood is possible, the use of 
recalcified citrated blood allows for prolonged sample stability. When the cup is 
placed in the instrument, it oscillates back and forth six times per minute with an 
angle of 4°45. The addition of caolin to the cup activates the coagulation cascade, 
leading to the formation of thrombin and subsequently the formation of fibrin and a 
clot. A pin attached to a stationary wire is immersed into the sample and monitors the 
strength and stability of the clot formation. The dynamic changes occurring as the clot 
formation progresses is measured, and converted into a curve. Different phases of the 
clotting process give rise to different parameters in the thromboelastogram. A 
standard TEG tracing obtained from citrated whole blood is shown in figure 3.2. 
 
 
 
Figure 3.2: A TEG tracing gives information about the coagulation factors (R), fibrin (angle), 
platelet function (MA) and fibrinolyse (LY30). The figure is adopted from Rai et al., 2003(110) 
 
 
The parameters obtained from the TEG tracing indicates following: 
R-time represents the time from initiation of the test to the first formation of fibrin. 
k-time is the time taken from the start of the clot formation until the amplitude of the 
tromboelastogram reaches 20 mm and indicates clot kinetic.  
α-angle is the angel between the baseline and the tangent to the curve and represents 
the kinetic of fibrin formation and cross-linking.  
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Maximal amplitude (MA) indicates the strength of the clot, and is a direct 
measurement of the highest point on the TEG curve.  
LY30 represents the cloth strength 30 minutes after MA is reached and provides 
information about the fibrinolytic activity.  
 
TEG is a rather simple and rapid procedure to perform, and its application is 
increasing. Some current clinical applications include monitoring haemostasis in 
trauma patients, assessing coagulation problems during liver and cardiac surgery, and 
monitoring treatment response in patient with bleeding disorder (111). 
3.2.2 Practical test procedure 
The TEG analyses were performed on a TEG® 5000, version 4.2 (Haemoscope 
Corporation, Niles, IL, USA). 
Day 0: 1 ml citrated whole blood was added to a caolin vial (Haemoscope 
Corporation, Niles, IL, USA) and gently mixed by inversion. 20 µL CaCl2 (B.Brown, 
Melsungen, Germany) and 340 µl of the caolin-treated citrate blood in the vial were 
then added to a neutral cup (Haemoscope Corporation, Niles, IL, USA) and the test 
was run.  
Day 1 and 5: 330 µl platelet concentrate together with 30 µl CaCl2 (B.Brown, 
Melsunge, Germany) was added to a neutral cup (Haemoscope Corporation, Niles, IL, 
USA) and the test was run.  
3.3 Platelet count 
3.3.1 Principles of the method  
Estimation of platelet concentration is a frequently used quality assessment to confirm 
that platelet units meet requirements for an acceptable donation. The impedance 
method is the most accurate method of platelet count (PLT) estimation in PC and is 
based on the measurement of changes in electrical resistance caused by cells in a 
buffered electrolyte solution. The non-conducting blood cells are forced through an 
aperture and thereby alter electrical charge between two electrodes. Pulses that are 
proportional to the volume of an individual cell are generated, and the count is 
determined from the total number of pulses produced from a measured volume of 
blood.  
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3.3.2 Practical test procedure 
Platelet concentrations were determined by the impedance method (CELL-DYN 
Sapphire, Abbott Diagnostic, IL, USA) on day 1 and 5 of platelet storage and in PRP 
on day of donation. The PRP was diluted 1:10 with PBS prior to the analysis.  
3.4 Analysis of pH, pO2 and CO2 
3.4.1 Principles of the method  
Ion selective electrodes are used to measure pCO2 and pH in clinical laboratories. The 
principle of the operation is measurement of the potential of a specific ion in solution 
against a stable reference electrode of constant potential. The method is based on the 
technique of potentiometry, which is the measurement of electrical potential without a 
current flowing. pO2 are measured based on the process of amperometry which is the 
measurement of a current flowing through at a constant potential.  
3.4.2 Practical test procedure  
Examination of pH and blood gas was performed on storage days 1 and 5 (ABL 725, 
Radiometer Copenhagen, Denmark; Modular, Hitachi High-Technologies corp., 
Tokyo, Japan).  
3.5 Recording of swirling  
3.5.1 Principles of the method  
Visual inspection of the swirling phenomenon is a simple and frequently used test for 
assessing the quality of stored platelet concentrates before transfusion. The swirling 
effect correlates with the in vitro transformation of platelets from disk to spiny 
spheres. When platelets are held up to a light source and gently agitated, discoid 
platelets will scatter incident light at all angels due to change in orientation relative to 
the incident light. Platelets, which have undergone transformation to spheres, have 
immediately very little ability to change orientation. The swirling phenomenon is 
consequently not observed in transformed platelets. Degree of swirling is usually 
scored from 0 (no swirling) to 3 (maximal swirling).  
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Figure 3.3: A, when platelets are held up to a light source and gently agitated, swirling platelet 
scatter incident light at all angles because platelets change orientation relative to the incident 
light. B, The swirling phenomenon is not observed in discoid platelets because of their decreased 
ability to change orientation and scatter light. Adapted by Maurer-Spurej & Chipperfield, 2007 
(112). 
3.5.2 Practical test procedure  
Visual inspection of the swirling phenomena was performed on SDC on day 1 and 5 
of platelet storage.  
3.6 Flow cytometry 
3.6.1 Principles of the method  
Flow cytometry is a technique for measuring and analyzing single particles, usually 
cells, as they pass down a fluid stream through a beam of light. The important feature 
of flow cytometric analysis is that measurements are obtained from each separate 
particle within the suspension, rather than an average value of the whole population.  
Flow cytometric analysis uses the principles of light scattering and fluorescence to 
measure multiple cellular parameters. The use of flow cytometry for cell sorting is 
also possible. The application of the flow cytometric technology is numerous in both 
research and in medicine. The major clinical application is diagnosis of hematologic 
malignancy. 
 
A flow cytometer is made of 3 components: the fluid system, the optics and the 
electronics.  
 
The fluid system: 
A fluid system is responsible for carrying the particles in the sample to the laser 
intercept. For accurate data collection, it is important that the particles and the cells 
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pass through the laser beam one at a time. Most flow cytometries accomplish this by 
injecting the sample in the centre of a sheath fluid and subsequently using the 
principle of hydrodynamic focusing. Due to a pressurized laminar flow, the sheath 
fluid causes the sample to remain in a central core as it flows within the flow cell one 
by one along their long axis.  
 
The optic part:  
Optics are central to flow cytometry for the detection of scatter and fluorescent light 
signals. The optical system in a flow cytometer consists of excitation optics and 
collection optics. The excitation optics is made up of the laser and lenses that are 
responsible for focusing the laser beam. The fluid system flows perpendicularly to the 
beam, and the point at which stream and light beam intersect is called the 
interrogation point. As a cell passes through the interrogation point it will scatter light 
at all angels. The extent to which this occurs is dependent on the physical properties 
on the particles in the sample. Forward scatter (FSC) or low angel scatter is the 
amount of light scattered in the forward direction. The magnitude of the forward 
scatter is roughly proportional to the size of the particle. Side scatter (SSC) is light 
scatter at larger angels and is caused by granularity and complexity inside the cell. 
Forward and side scatter are used for preliminary identification of cells. 
 
The addition of labelling cell surfaces or antigens in the cells cytoplasm by antibodies 
conjugated with fluorescents like PE and FITC, allows for the investigation of cell 
structure and function. Absorption of light from the laser beam as the cell passes 
through the interrogation point causes an electron in the fluorochrom molecule to be 
raised to a higher energy level. The excited electron is unstable, and drops to its 
original ground state and emits the excess energy as a photon of light. This transition 
of energy is termed fluorescence, and can be detected in a flow cytometer along with 
scattered light.  
 
The collection optics are responsible for collecting light as it emerges after 
intersection with the stream. A combination of optical filters and mirrors direct 
scattered and fluorescent light to appropriate detectors. Emitted SSC and fluorescence 
signals are directed to the photomultiplier tubes located 90 degrees to the laser beam. 
FSC signals are diverted to photodiodes along the axis of the laser beam.  
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The electronics 
Particles are analysed individually but interpreted collectively. Light signals 
generated as particles flow through the laser beam are converted to electronic signals 
by the photodetectors. The electronic signals are proportional to the optical signals 
striking the detectors. Numerous options for displaying and analyzing collected data 
are available in today’s software program. Histograms and dot plots are most 
frequently used for representing flow cytometric data. Single parameters such as FSC, 
SSC or a fluorochrom signal can be displayed as a single-parameter histogram, where 
the horizontal axis represents the intensity of the detected signal and the vertical axis 
represents the number of events (cells) counted. Dot plots provide a two-parameter 
display of data. In a dot plot each cell represents one dot, positioned on the horizontal 
axis and vertical axis according to the intensities detected for that cell.  
Figure 3.4 summarizes the most important components in a flow cytometer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: Components of a generalized  “four parameter” flow cytometer. The figure is 
adapted from Givani, 2001 (113) and modified.  
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3.6.2 Practical test procedure 
 
Flow cytometric platelet activation analysis was performed on platelets stored under 
routine blood bank condition on storage day 1 and 5. The platelet population was 
identified by light-scatter characteristics and FITC-conjugated CD61- spesific 
monoclonal antibody (DAKO, Glostrup, Denmark). Light scatter and fluroresence 
data from 10,000 CD61-positive events were collected with al detectors in 
logarithmic mode. The platelets were exposed to agonists, including thrombin 
receptor activator peptide (TRAP) (Sigma-Aldrich, St.Louise, USA) and two different 
concentrations of ADP (Sigma-Aldrich, St.Louise, MO, USA) before stained with 
PE-conjugated CD62P- spesific monoclonal antibody (DAKO, Glostrup, Denmark) 
and PE-conjugated CD42b specific monoclonal antibody (BD Pharmingen, San 
Diego, CA, USA). The final agonist concentrations in the samples include 100 µM 
TRAP, 10 µM ADP and 1 µM ADP. For each activation point, a negative matched 
IgG control conjugated with PE was carried out in parallel. Median fluorescence 
intensity of positive cell population was estimated for each antigen. The fluroresence 
resulting from the binding of matched IgG control was set to 1%. In addition to 
expression of platelet surface glycoproteins, the extent of platelet microparticles 
generation was examined. A nonfluorescent Size Calibration kit (Molecular Probes, 
Eugene, ORE, USA) containing suspended polystyrene mircrospheres with different 
diameter was used to determine sizes. MPs were defined as elements with size less 
than 1.0 µm. 
The flow cytometric analysis was performed on a FACS Calibur (BD Biosciences, 
San Jose, CA, USA) equipped with CELLQuest® software (BD Biosciences, San 
Jose, CA, USA). 
3.7 Chromatography and mass spectrometry 
We used high performance liquid chromatography (HPLC) combined with 
electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS) to determine 
tryptophan and tryptophan metabolites and HPLC together with a fluorescent detector 
to determine serotonin.  
 
HPLC is an improved form of column chromatography used to separate, identify, 
purify and quantify chemical compounds. Chromatography uses the principle of 
  38 
differences in surface interaction between analyte and eluent molecules to separate 
compounds within one sample. In HPLC, the analytic instrument composes two main 
phases. The stationary phase (absorbend) is the solid support situated within the 
column. The mobile phase (eluent) in HPLC refers to the solvent, which is continually 
added to the column. When injecting a sample into the instrument it will migrate 
through the column according to its affinity to the mobile phase and stationary phase. 
Compounds having stronger interaction with the mobile phase than the stationary 
phase will elute more quickly than compounds having stronger affinity to the mobile 
phase. In HPLC, applied pressure ensures that the analyte and the mobile phase are 
forced through the densely packed column. Quantitative analysis of biomolecules by 
the use of HPLC is achieved by preparation of standard curves.  
3.7.1 LC-ESI-MS/MS 
3.7.1.1 Principal of the method  
The effluent from the HPLC-column is introduced into the mass spectrometer and 
enters the ionization chamber through a capillary to which a 3-5 kV charge has been 
applied. Charged droplets emerge from the tip of the capillary and the charge-to-
volume ratio increases as the droplets evaporate. Positive charges are repelled and 
free proton-adducts of the molecules emerge. The adducts are selected in an 
electromagnetic field in the first quadropole according to their mass-to-charge ratios 
(m/z). They then enter the second quadropole, where they are collided with gas 
molecules, usually nitrogen, and fragmented to form product ions. Usually the most 
abundant product ion is selected in the third quadropole according to its mass/charge 
ratio and allowed to reach the detector. Because MS/MS is a selective method, several 
ions may be measured even if they are not chromatographically separated. This is 
achieved by monitoring several molecular transitions intermittently, so called multiple 
reaction monitoring (MRM). The amount of analyte in a sample does not correlate 
directly with the ion-current intensity of its mass spectrometric signal. To calculate 
analyte concentrations, an internal standard is contained in the sample. The internal 
standard should be chemically similar to the compound that is to be measured, ideally 
an isotopic analogue. Peak area ratios are calculated between the analyte and the 
internal standard and used to calculate concentrations by using a standard curve, 
which is obtained by analysing several samples containing know amounts of the 
compound to be determined.  
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3.7.1.2 Practical test procedure 
LC-ESI-MS/MS was used for the quantitative analysis of tryptophan and tryptophan 
metabolites in EDTA plasma. The plasma was first deproteinized by adding an equal 
volume of thrichoracetic acid (Merck Whitehouse Station, NJ, USA) in water (60 g/l) 
containing the isotope labelled internal standards (100 nmol/l of 2H5-KA and 2H4-AA, 
200 nmol/l of  2H4-kyneruine, and 2 µmol/l of 2H5- tryptophan). A robotic workstation 
(MicrolabAT Plus, Reno, NV, USA) carried out the precipitation step, before the 
solution was left on ice for 60 min and finally centrifuged at 5796 x g at 4ºC for 15 
minutes. The supernatant (60 µl) was added to a new vial before being placed in a 
cooled (8ºC) autosampler. The analysis was performed on an API 4000 triple-
quadrupole tandem mass spectrometer (Applied Biosystems/MDS SCIEX, Foster 
City, CA, USA) with electronspray ionization.  The instrument was equipped with 
Analyst v.1.4.1 software (Applied Biosystems/MDS SCIEX, Foster City, CA, USA). 
3.7.2 HPLC combined with fluorescence detection 
3.7.2.1 Principle of the method 
Fluorescence detectors excite the analytes in the eluate with a laser and measure 
fluorescence. Detection techniques based on fluorescence are very sensitive 
independent of the sample concentration.  
3.7.2.2 Practical test procedure  
Preparation of platelet extracts: 
250 µl 24% percloric acid solution (Merck, Whithouse Station, NJ, USA) containing 
40 mmol dithiothreitol (DTT) (Sigma-Aldrich, St.Louise, MO, USA) per litre was 
mixed with 750 µl sample (PRP or SDC). After centrifugation at 8000 x g for 4 min 
(Biofuge A, Heraeus Sepatech, Germany) 600 µl of the supernatant was added to a 
new tube, and neutralized with 150 µl 3 M K2HPO4 (Sigma-Aldrich, St.Louise, MO, 
USA) before stored at -80°C until use.  
On the day of HPLC analysis, the precipitated potassium perchlorate was removed by 
a new centrifugation (Mikro 200R, Hettich Zentrifugen, Hettich, Kirchlengern, 
Germany) and samples of the supernate (20 µl) were injected directly into the liquid 
chromatograph.  
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Preparation of standard: 
A standard stock solution of 1 mmol/l serotonin (Sigma-Aldrich, St.Louise, MO, 
USA) was prepared in water containing 10 mmol/l DTT (Sigma-Aldrich, St.Louise, 
MO, USA). Neutralized perchloric acid (Merck, Whithouse Station, NJ, USA) with 
the same composition as obtained in the standard extraction procedure of platelets, 
was then used to dilute the stock solution to obtain standard samples with 
concentration of serotonin within the range of 0.6 µM to 6.0 µM.  Two different 
standard curves were then obtained as shown in figure 3.5 and figure 3.6.   
 
Figure 3.5: Standard curve obtained from samples with serotonin concentrations in the range of 
0.6 µM to 2.4 µM.  
 
 
 
Figure 3.6: Standard curve obtained from samples with serotonin concentrations in the range of 
3.06 µM to 6.0 µM 
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Liquid chromatographic analyses of serotonin: 
The liquid chromatograph consisted of a Spectra System P4000 pump (SP Thermo 
Separation products, San Jose, CA, USA), a Gilson 232 XL autosampler (Gilson, 
Villiers-le-Bel, France) and a LaChrom L-7480 fluorescence detector (Merck, 
Whitehouse Station, NJ, USA) For the chromatographic separation of serotonin a 
cation-exchange column (Zorbax SCX, 4.6x150 mm, Agilent, Santa Clara, CA, USA) 
with sodium acetate (pH 5.2, 150 mmol/l) (Merck, Whithouse Station, NJ, USA) 
containing 10 ml of 1-propanol (Merck, Whithouse Station, NJ, USA) per litre as the 
mobile phase was used. The instrument was equipped with PC1000 System Software 
(SP Thermo Separation products, San Jose, CA, USA).  
3.8 Statistical analysis 
Descriptive statistics and statistical hypothesis testing were performed by the use of 
SPSS16 for Mac (SPSS, Chicago, IL, USA). Because most data obtained showed a 
non-symmetrical distribution, only non-parametric tests were performed. The Mann 
Whitney U test was used to compare the observations from the test and the control 
group. A p-value less than 0.05 was considered significant.  
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4 Results 
4.1 Platelet aggregation 
Data from the platelet aggregation testing by the LTA method are given in Table 4.1.  
Table 4.1. The results from the platelet aggregation assay  
 Parameter 
  
   Agonist 
 
Test group (n=8) 
 
 
Control group (n=10) 
 
P 
20 µM ADP 35.5 (23-65) 28 (14-73) 0.247 Max 
aggregation 
(%) 50 µM ADP 53.5 (34-72) 59 (27-80) 0.350 
20 µM ADP 54 (45-71) 47 (35-82) 0.230 Velocity 
(%/min) 50 µM ADP 60.5 (49-100) 66 (34-440) 0.460 
The results from the calculated parameters max aggregation and the velocity are given as the 
median (range). 
 
As expected, the platelet aggregation response for both the test- and the control group 
was much greater when adding 50 µM ADP compared to adding 20 µM ADP. The 
lowest concentration of ADP induced reversible aggregation for all individuals, 
except one, which showed irreversible aggregation. The highest concentration of ADP 
produced irreversible aggregation for all individuals, and gave and much higher 
calculated values for max aggregation and velocity. The p-values (Table 4.1) indicate 
no statistical significant differences concerning max aggregation response and 
velocity (%/min) response using ADP as agonist for blood donors using SRI 
compared to blood donor using no medication. Figure 4.1 show examples of the 
aggregations curves for the two concentrations of ADP for one individual included in 
the study. 
A                                                               B 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: The use of 20 µM ADP as agonist gave a reversible aggregation response (A), whereas 
50 µM ADP induced an irreversible aggregation response (B).   
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4.2 Thrombelastography  
Data from the thrombelastography analysis are given in Table 4.2.  
Table 4.2: The results from the TEG analysis 
Parameter Day Test group (n=8) Control group (n=10) P 
0 10.7 (8.2-12.0) 9.25 (7.5-14.2) 0.722 
1 13.3 (9.7-20.8) 14.05 (8.1-20.9) 0.756 R (min) 
5 17.2 (12.4-28.70) 17.75 (11.8-21.5) 0.964 
0 2.9 (1.8-3.6) 2.4 (1.8-3.5) 0.167 
1 1.8 (1.1-3.9) 1.9 (1.0-4.8) 0.656 k (min) 
5 2.1 (1.2-4.2) 2.2 (1.2-5.0) 0.721 
0 51.9 (48.3-63.3) 56.9 (48.0-66.7) 0.142 
1 64.50 (50.5-74.6) 64.2 (40.1-75.3) 0.657 Angle (°) 
5 63.3 (42.4-74.1) 60.45 (44.9-74.8) 0.286 
0 59.0 (53.6-67.2) 62.85 (53.7-67.9) 0.131 
1 65.3 (63.2-77.8) 66.8 (55.3-74.2) 1.000 MA (mm) 
5 70.7 (63.3-74.8) 69.6 (58.2-74.30) 0.563 
The results from the TEG analysis are given as the median (range) of the parameters R, k, angle 
and MA for the test and the control group. 
 
There were no significant difference between the test group and the control group 
regarding the parameters obtained from the thromboelastography analysis. This 
observation was done for analysis in both PRP and SDC and on both day 1 and day 5 
of platelet storage. Figure 4.2 and 4.3 show examples of TEG curves obtained from 
one individual included in the study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: TEG tracing obtained from a SDC on storage day 1.  
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Figure 4.3: TEG tracing obtained from the same SDC as in figure 4.2, but now on storage day 
five. 
4.3 Platelet content 
Table 4.3 presents the results from the calculation of the platelet content in SDC 
based on PLT and measurement of the weight of the SDC. The parameter is expressed 
as total numbers of platelets in a SDC. During day 1 to day 5 of platelet storage, the 
platelet content was decreased in all SDC.  
 
Table 4.3: The results from the calculation of the platelet content in SDC 
Parameter Day Test group (n=8) Control group (n=10) P 
1 366 (316-480) 418 (244-537) 0.328  
Platelet content 
(=109) 
 
5 296 (249-409) 343 (211-465) 0.285 
The results from the platelet count in SDC for the test group and the control group are given as 
the median (range). 
 
The calculated p-values (Table 4.3) indicate that there are no statistical significant 
differences concerning the total numbers for platelet in SDC for the test group and the 
control group on both storage days.  Except one case, all SDC met the requirement 
regarding a minimum content of 240x109 platelets.  
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4.4 pH, pO2, pCO2 
 
Analysis of blood gas 
Data from the analysis of blood gas in SDC during storage are given in Table 4.5.  
Table 4.5: The results from the analysis of blood gas 
Parameter Day Test group (n=8) Control group (n=10) P 
1 15.23 (12.50-19.57) 16.03 (11.50-21.32) 0.722 
pO2 (kPa) 
5 17.47 (15.95-19.95) 17.85 (12.60-19.51) 0.965 
1 3.68 (3.31-4.99) 3.78 (2.61-4.33) 0.505 
pCO2 (kPa) 
5 3.15 (2.53-3.45) 3.09 (2.38-4.08) 0.213 
The results from the analysis of pO2 and pCO2 in SDC during storage are given as the median 
(range). 
 
pO2 increased from day 1 to day 5 of storage, whereas pCO2 decreased from day 1 to 
day 5 for all SDCs. The p-values (Table 4.5) indicate that no statistical significant 
differences were detected regarding the analysis of blood gas on both storage days for 
blood donors using SRI and blood donors using no medication.  
 
Analysis of pH 
In Table 4.6 the results from the pH analysis in SDC during storage are presented.  
Table 4.6: The results from the pH analysis 
Parameter Day Test-group (n=8) Control-group (n=10) P 
1 7.11(7.00-7.21) 7.17(7.10-7.23) 0.076 pH 
5 7.02(6.90-7.13) 7.09(7.03-7.14) 0.068 
The results from the analysis of pH on storage days 1 and five are given as the median (range). 
 
pH decreased from day 1 to day 5 of storage for all SDCs.  No significant difference 
in median values was observed between the test and the control group on both storage 
days.  
4.5 Swirling  
No difference was obtained between the test group and the control group regarding 
the recording of the swirling phenomenon, since all SDCs were given the score 3 on 
storage days 1 and 5. 
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4.6 Platelet glycoprotein expression and microparticle formation 
 
Spontaneous and agonist-induced glycoprotein expression 
The results from the spontaneous glycoprotein expression are presented in Table 4.7.  
Table 4.7: Spotaneous glycoprotein expression  
Parameter Day Test group (n=8) Control group (n=10) P 
1 50.3 (21.9-56.7) 33.1 (15.0-38.5) 0.041 Spontaneous 
CD62P 
expression 5 35.1 (21.5-50.5) 27.5 (14.2-46.1) 0.266 
1 294.6 (222.7-381.8) 355.5 (257.1-382.0) 0.247 Spontaneous 
CD42b 
expression 5 277.7 (201.0-388.9) 310.6 (246.9-349.1) 0.230 
The results from the spontaneous expression of CD62P and CD42b are given as the median 
(range). 
 
A p-value of 0.041 indicates a statistical significant expression of spontaneous CD62P 
on day 1 of platelet storage. Surprisingly, the observation shows that it is the test 
group that have greater spontaneous CD62P expression relative to the control group. 
Spontaneous CD62P expression on day 5 and spontaneous CD42b expression on day 
1 and 5 show no significant difference for the blood donors using SRI and blood 
donors without medication.  
 
Platelet activation capacity expressed as upregulation of CD62P and downregulation 
of CD42b in response to agonists were evaluated by comparing calculated median 
activation ratios (agonist-induced glycoprotein expression/spontaneous glycoprotein 
expression) for the test and control group.  The results from the study of agonist-
induced CD62P expression are given in Table 4.8.  
 
Table 4.8: Flow cytometric analysis of CD62P  
Parameter Day Test group (n=8) Control group (n=10) P 
1 0.97 (0.91-1.04) 0.94 (0.86-1.03) 0.286 Median 
activation ratio 
1 µM ADP 5 0.97 (0.92-1.06) 0.96 (0.84-1.07) 0.594 
1 1.00 (0.94-1.30) 0.96 (0.90-1.20) 0.374 Median activation ratio 
10 µM ADP 5 1.02 (0.95-1.37) 0.98 (0.81-1.41) 0.286 
1 2.30 (1.76-6.04) 4.18 (2.89-6.61) 0.760 Median 
activation ratio 
TRAP 5 3.35 (1.95-7.17) 4.06 (2.15-7.57) 0.408 
Flow cytometric analysis of CD62P expression in response to agonists was evaluated by the 
calculation of median activation rations. The results are given as the median (range). 
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The p-values (Table 4.8) indicate that there were no statistical significant differences 
in calculated median activation ratios for CD62P in the test and control group. This 
observation was done on both day 1 and day 5 of platelet storage. Figure 4.4 presents 
dot plots obtained from samples from the same SDC, incubated with anti-CD61 (FL1) 
and anti-CD62P (FL2), but with different agonists.  
 
A                                                     B 
 
 
                                                        
 
 
C                                                     D 
                                                    
 
 
 
 
 
Figure 4.4: Dot plots representing CD61 (FL1) and CD62P (FL2) expression at:  A) Baseline, B) 
induced by 1 µM ADP C) induced by 10 µM ADP and D) induced by 100 µM TRAP (C) for the 
same individual.  
 
As seen in Table 4.8, the platelet activation response to ADP gave a median activation 
close to 1 for both groups and on both storage days, whereas TRAP had greater ability 
to induce changes in CD62P expression relative to the baseline. This trend can also be 
observed in Figure 4.4. Here, CD62P expression at baseline (A), induced by 1 µM 
ADP (B) and induced by 10 µm ADP (C) show almost identical dot plots, reflecting 
the fact that the quantitative percentages of cells expressing CD62P is similar. In 
contrast, the platelets stimulated with 100 µm TRAP (D) show greater expression of 
CD62P, as more dots are situated in the upper right quadrant.  
 
The results from the study of agonist-induced CD42b expression are given in Table 
4.9.  
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Table 4.9: Flow cytometric analysis of CD42b expression  
Parameter Day Test group (n=8) Control group (n=10) P 
1 0.99 (0.91-1.19) 0.98 (0.86-1.37) 0.929 Median 
activation ratio 
1 µM ADP 5 0.96 (0.86-1.11) 1.03 (0.99-1.35) 0.006 
1 0.93 (0.63-1.05) 0.88 (0.62-1.29) 0.374 Median 
activation ratio 
10 µM ADP 5 0.92 (0.74-0.98) 0.96 (0.81-1.24) 0.183 
1 0.52 (0.26-0.69) 0.45 (0.24-0.63) 0.155 Median 
activation ratio 
TRAP 5 0.49 (0.29-0.62) 0.47 (0.38-0.70) 0.790 
Flow cytometric analysis of CD42b expression was evaluated by the calculation of median 
activation rations. The data are given as the median (range). 
 
A p-value of 0.006 (Table 4.9) reveals a significant difference between the test and 
control group, when it comes to the median activation ratio for 1 µm ADP on day 1. 
The CD42b expression is highest in the control group. 
The expression of CD42b on day one for 1 µm ADP and for the other activation steps, 
show no difference between the test and control group. Figure 4.5 show dot plots 
obtained from samples from the same SDC incubated with anti- CD61 (FL1) and 
CD42b (FL2). Each dot plot represents one activation step.  
A                                                      B 
 
 
 
 
 
 
 
 
 
C                                                       D 
 
   
   
 
 
 
 
Figure 4.5: Dot plots representing CD61 (FL1) and CD42b (FL2) expression at: Baseline (A), 
induced by 5 µM ADP (B), induced by 50 µM ADP and induced by 500 µM TRAP (C) 
 
As seen in Table 4.10, the analysis of agonist induced CD42b expression also gave 
median platelet activation ratios close to 1 in response to ADP, whereas TRAP had 
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greater ability to induce a decrease in CD42b expression. This observation is, 
however, more difficult to detect when studying the dot plots in figure 4.5 compared 
to the dot plots in figure 4.4. Here, the dot plots are almost equal for the different 
activations steps, reflecting that the quantitative percentages of cells expressing 
CD42b is much similar. However, it is the magnitude of the fluorescence intensity, 
which makes it possible to observe a difference in CD42b expression for platelets 
stimulated ADP and TRAP.  This difference in fluorescence intensity must be due to 
the fact that expression of CD42b per platelet is greater for samples stimulated with 
ADP compared to TRAP.  
 
Agonist induced microparticles formation 
Figure 4.6 show examples of dot plots obtained from flow cytometric analysis of two 
different SDC activated with TRAP on the same storage day. 
 
 
A                                                      B 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6: Dot plots from two different SDC activated with the same agonist on the same platelet 
storage day. In A, a circle is drawn around the microparticle population, which is easily detected. 
In B, the platelet population is shifted to the left in the dot plot, and the microparticles cannot be 
observed 
 
Technical problems are the reason for the observed phenomenon in Figure 4.6. In A, 
the microparticle population is easily observed in the dot plot and a circle is drawn 
around the population. However, in B, the platelet population is shifted to the left in 
the dot plot, making it impossible to obtain information about microparticle 
formation. The trend regarding shifted population was independent of storage days, 
agonist used, and on the test and control group. Due to this technical challenge, it is 
problematic to compare platelet microparticle formation for the test and control 
group. 
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4.7 Tryptophan, tryptophan metabolites and serotonin 
 
Tryptophan and tryptophan metabolites 
The results from the quantitative analysis of tryptophan and some important 
tryptophan metabolites are given in Table 4.11.  
 
Table 4.10: The results from the analysis of tryptophan and tryptophan metabolites 
Parameter Test group (n=9) Control group (n=10) P 
Tryptophan (µM) 86.8 (66.85-102.18) 78.45 (68.52-95.15) 0.424 
Kynurenine (nM) 1.62 (1.25-2.01) 1.73 (1.08-2.01) 0.824 
Kynurenic acid (nM) 40.1 (29.85-82.73) 40.92 (16.64-69.66) 0.328 
Xanthurenic acid (nM) 20.7 (2.60-31.88) 16.21 (7.49-34.95) 0.424 
Anthralinic acid (nM) 6.67 (4.82-9.47) 6.54 (3.78-10.18) 1.000 
Data from the quantitative analysis of tryptophan and tryptophan metabolites are given as the 
median (range) for the test and control group. 
 
The p-values (Table 4.11) show no statistical significant differences between blood 
donors using SRI and blood donors using no medication when it comes to tryptophan 
content and the content of some of the most important metabolites of tryptophan.  
 
Serotonin  
Quantitative analysis of serotonin by the use of HPLC was achieved by constructing 
standard curves with serotonin concentrations within the range of normal serotonin 
content in human blood. The serotonin content was analysed on day of donation in 
PRP and in SDC on storage days 1 and 5.  
Two analyses from each sample material were carried out in parallel, and the mean 
value was calculated. The results presented in Table 4.11 and 4.12 are based on this 
calculation. 
 
Table 4.11. Serotonin content in PRP on donation day 
Parameter Test group  (n=8) 
Control group 
(n=10) P 
serotonin content 
(nmol/109 platelet) <0.6 (<0.6) 1.97 (0.85-2.96) 0.0004 
Serotonin content measured in PRP on day of donation is give as the median (range). All the 
individuals in the test groups had serotonin content <0.6 nmol/109 platelet. 
 
 
 
 
  51 
 
Table 4.12: Serotonin content in SDC on storage days 1 and 5.  
Parameter Day Test group  (n=8) 
Control group 
(n=10) P 
1 <0.6 (<0.6) 1.70 (0.92-2.83) 0.0004 serotonin content 
(nmol/109 platelet) 2 <0.6 (<0.6) 1.89 (1.44-2.59) 0.0004 
Serotonin content measured in SDC on storage days 1 and 5 are given as the median (range). All 
the individuals in the test groups had serotonin content <0.6 nmol/109 platelet. 
 
 
The HPLC instrument we used in this study showed not to compose satisfying 
stability, and we meet a variety of technical challenges during analysis. This resulted 
in great variations between the two parallels in many data sets. We chose, however, to 
present the results as the mean value for the two parallels, and we included all values 
in statistical hypothesis testing because we observed an obvious difference in the two 
groups during analysis.  
 
The median values and the ranges from Table 4.11 and 4.12 indicate that the test 
group composes markedly lower serotonin content that the control group. This is also 
confirmed by the significant p-values. However, the great variation we experienced in 
many parallel data sets have to be taken into consideration when evaluating the p-
value. Despite this, the results indicate strongly that blood donors using SRI have 
clearly lower serotonin content in platelets compared to blood donors without 
medication.   
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5 Discussion  
  
Our prospective blinded randomized control study aimed to investigate platelet 
function in whole blood and in apheresis PCs between blood donors using SRI (n=8) 
and blood donors without medication (n=10). Qualitative analyses of tryptophan, 
tryptophan metabolites and serotonin were also undertaken. Light transmission 
aggregometry, trombelastography and flow cytometric analysis of glycoprotein 
expression did not detected altered platelet function in blood donors using SRI. The 
test group showed markedly lower platelet sertonin compared to the control group, 
while tryptophan and tryptophan metabolites shared no difference between the 
groups. Routine tests of stored platelets indicate high quality of PC obtained from 
blood donors using SRIs.  
The results from each different test performed in the study will be discussed 
separately, before an overall view of the study will be taken into consideration.  
5.1 Platelet aggregation 
Our results obtained from the platelet aggregation response using ADP as agonist, 
indicate that blood donors using SRI show no abnormalities in aggregation profiles 
compared to blood donors using no medication. We chose to include ADP as the 
agonist, because it has been postulated that serotonin dose-dependently enhances 
platelet activation induced by ADP (16).  
 
There are few published studies that have investigated the effect of SRIs on in vitro 
platelet aggregation. Moreover, the findings from these studies are conflicting. 
McCloskey et al. (19) compared aggregation responses in plasma between patients 
using SSRI and patient using a non-SSRI antidepressant (bupropion) and found no 
difference between the two groups when ADP at final concentration of 5.5 µM was 
used as a agonist. This finding is in line with our results. However, significant 
abnormalities in the SSRI patients were detected when 4.5 µg/ml collagen and 0.87 
mM arachidonic acid, which is a precursor for TXA2, were used as agonists. 
Serebruany et al. (114) studied the platelet aggregation response to 5 µM ADP and 
1µg/ml collagen in patients undergoing elective corononary artery stenting. They 
found that patients using SSRI showed significant depressed aggregation response 
  53 
compared to patients not using a SSRI. We could not reproduce the finding that the 
SSRI patients show abnormalities in ADP-induced aggregation.   
 
Most published studies that have investigated the influence of antidepressants on in 
vitro platelet aggregation, have used plasma preincubated with the drugs. Galan et al. 
(115) demonstrated that incubation with clinical relevant concentrations of 
escitalopram caused statistical reduction in aggregation induced by 0.5 µM and 2 µM 
ADP, although no difference were observed for 2.5 µg/ml collagen and 1.4 mM 
arachidonic acid. In contrast, Sarma et al. (116) reported that venlafaxine 
concentration at least 1000-fold greater than those used clinically were needed to 
demonstrate platelet aggregation abnormalities in response to 5.5 µM ADP, 2.2 µg/ml 
and 0.9 mM arachidonic acid. Serebruany et al. (117) showed that only high 
therapeutic doses of sertraline caused inhibition of aggregation induced by 5 µM and 
10 µM ADP.  
 
LTA has for more than 50 years been in use in hemostasis laboratories and is by many 
clinicians and researchers considered to be the “gold standard” for the evaluation of 
patients with defects in platelet function. However, the assay is prone to pre-analytical 
variables like blood collection, transportation and type of anticoagulant (118). In 
addition, many investigators standardize the platelet count in PRP before analysis 
(e.g. at 250 × 109 L−1). In our study, we did not standardize the platelet concentrate 
because studies have revealed that the processes needed to obtain a uniform platelet 
concentrate will always lead to some platelet activation and because aggregation 
response has not shown to change much between platelets counts of 150, 000 per µL 
and 450, 000 per µL (118).   
 
The effect of SRI on platelet aggregation is a matter of considerable controversy. 
Because of the lack of standardization of LTA, it may also be problematic to compare 
results from different studies. There is a need for further studies to clearly identify the 
effect of SRIs on platelet aggregation.  
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5.2 Thrombelastography  
 
Our TEG assay results indicate that blood donor using SRI show no abnormalities in 
the TEG tracing compared to blood donors without medication. Only one published 
study has investigated the effect of SRI on platelets by the use of assays that measures 
viscoelastic changes during coagulation. Galan et al. (115) applied ROTEM 
thrombelastometry to analyse whole blood exposed to serotonin without and with 
previous incubation with therapeutic doses of citalopram for 2 minutes. The method is 
considered to be an alternative to TEG, but in the ROTEM, the cup is held stationary 
while an oscillatory force in applied to the pin (119). As the blood clots, the decrease 
in the pin’s actually oscillation is measured. In standard conditions using citrated 
blood, Galan and co-workers observed no significant difference between samples 
exposed to only serotonin and samples exposed to both serotonin and citalopram.   
 
The use of conventional TEG has shown limitations in the assessment of platelet 
function in patients who use antiplatelet therapy like aspirin and clopidogrel (120). 
While aspirin inhibits the formation of TXA2, clopidogrel inhibits the P2Y12 receptors 
on the platelet surface. Normally, activation of the platelet TXA2 and ADP receptors 
cause activation of the GPIIb/IIIa receptor, which plays a key role in platelet 
aggregation. Standard TEG MA is a direct function of the maximum dynamic 
properties of fibrin and platelet bonding via GPIIb/IIIa and represents the ultimate 
strength of the fibrin cloth (121). Standard TEG is insensitive to platelet inhibitors 
because of the use of citrated blood, which allows for thrombin generation when 
CaCl2 is added during the testing process. The powerful platelet activator thrombin 
bypasses the less-potent platelet activators like ADP and TXA2, making assessment of 
their contribution to platelet activation impossible. Because serotonin is believed to be 
an amplifier of platelet aggregation through other activators like ADP, it is possible 
that the effects of SRI therapy is not detectable in standard TEG for the same reasons 
as aspirin and clopidogrel.  
It would be interesting to study the effect of SRI in the TEG Platelet Mapping assay, 
which is a modified form of TEG. The particular advantage of the TEG Platelet 
Mapping is that it measures the platelet contribution to the clot strength in addition to 
platelet function. This assay has also shown to be suitable for monitoring antiplatelet 
therapy (122).  
  55 
5.3 Platelet content  
We did not detect a significant difference concerning the platelet content between 
SDCs obtained from blood donors using SRI and blood donors without medication.  
A decreased concentration of platelets was observed from day 1 to day 5 during 
storage. This was expected due to the platelet storage lesion. However, all SDCs used 
in this study met the requirement of a minimum content of 240x109 platelets (101), 
except one, which had a content of 211 x109 platelets on storage day 5. This was not 
relevant for our study, as none of the SDCs were transfused.  
 
5.4 pH, pCO2 and pO2 
Metabolic parameters such as pH, pO2 and pCO2 are considered as reliable quality 
markers of platelet concentrate during storage (123). We did not detect a significant 
difference between SDCs obtained from blood donors using SRI compared to the 
control group when it comes to pH. As expected, we detected a fall in pH from day 
one to day five of storage for all SDCs obtained in the study. Platelets are metabolic 
active, and a fall in pH correlates strongly with a rise in lactate concentration. The 
subsequent formation of CO2 during glycolysis also contributes to a fall in pH (124). 
In our study we found the lowest pH value to be 6.90 and the highest pH value to be 
7.23. Previous studies have shown that pH < 6.0 or pH > 7.6 results in low platelet 
viability (125, 126). Thus, all PC used in our study were in line with quality criteria 
based on pH measurement. 
 
We observed no significant differences in blood gas during storage between the test 
and control group. To maintain an adequate pH in platelet during storage at 22°C, it is 
important that the storage containers have sufficient permeability for O2 and CO2 
(126). Data from our study shows that all SDCs were able to maintain pO2 and pCO2 
within acceptable ranges, reflected by the fact that pH did not change to values 
associated with low in vivo viability.  
 
5.5 Swirling 
 
In our study swirling with the score 3 was observed in all SDCs on both day one and 
day five of storage. The presence of the swirling phenomenon has shown to correlate 
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with a pH value in the range of 6.7-7.5 (126), which is confirmed from the results 
from the measurement of pH as referred to in section 4.5.  
 
5.6 Platelet glycoprotein expression and microparticle formation 
 
Platelet glycoprotein expression  
The results from the flow cytometric analyses indicate that blood donors using SRIs 
do not have altered platelet glycoprotein that indicates depressed platelet function.  
Platelet glycoprotein expression in patients receiving SRI therapy has previously been 
investigated, but in a limited number of studies. Moreover, no studies have evaluated 
the effect of SRI on platelets during storage. It is difficult to compare our findings 
with previous studies for many reasons. First of all, previous studies have mostly 
aimed to evaluate glycoprotein expression before and after SRI therapy, and not in 
comparison with a control group. The results from these studies suggest that 
depressed patients shown increased platelet activation, and that SRI treatment is 
associated with a beneficial protection against cardiovascular mortality, as SRI can 
cause normalization of platelet activation (117, 127, 128). Moreover, some of the 
studies have investigated platelet activation reflected by enhanced content of the 
soluble form of P-selectin in plasma. P-selectin can be cleaved from the platelet 
surface by the action of proteases. The prediction that soluble P-selectin reflects 
platelet activation may be questioned as platelets can shed or reinternalise this protein 
after activation, and due to the possibility of recycling during later activation (129, 
130). We therefore considered the membrane form of P-selectin as the most reliable 
parameter. In summary, the published studies on platelet glycoprotein expression in 
patients undergoing SRI therapy show conflicting results. There is a need for further 
studies to clearly identify this effect of SRIs.  
 
Interestingly, we found significant decreased ADP-induced CD42b expression on day 
5 (p=0.006) and borderline significant increased spontaneous expression of CD62P on 
day 1 (p=0.041) in the test group.  These findings may be without biological 
importance since none of the other parameters concerning glycoprotein expression 
were significant. However, there are studies that have revealed that patients with 
depressive disorders are at increased risk for developing ischemic heart disease, and 
many studies have reported increased platelet activation in these patients (127, 128). 
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Also, three of the individuals in the test groups used venlafaxine, which have 
suggested to promote adverse cardiovascular events by increasing platelet activity in 
susceptible patients (131). 
 
Several published studies have demonstrated changes in glycoprotein expression on 
platelet surface as a part of the process known as the platelet storage lesion. In our 
study we found a relatively high spontaneous expression of CD62P and a low 
expression of CD42b for both the test and the control groups. In addition, the platelet 
activation response to ADP gave a median activation ratio close to 1 for both groups 
and both antibodies, indicating that flow cytometric analyses does not show major 
significant differences in platelet activation in response to ADP. These findings 
suggest that preparation and storage of platelet concentrate causes activation of 
platelets, and that ADP is a too weak agonist to induce further activation. It would 
have been interesting to study the glycoprotein expression using whole blood flow 
cytometry to see to what extent the platelets are activated during the processing and 
storage of platelet concentrates.  
 
Agonist induced microparticle formation 
 
In this study we were not able compare MP formation in the test and control group 
due to the technical problems explained in chapter 4.6. The unimodal decrease (or 
left-shift) in forward angle light scatter we observed in our study is previous reported 
as a typical data presentation under routine flow cytometric settings (132). It has been 
suggested that this unimodal decrease represents really degranulated platelets (132). 
 
5.7 Relationship to epidemiological studies  
The first epidemiological evidence concerning the association between bleeding risk 
and antidepressant with a relevant blockade on the serotonin reuptake was published 
in 1999. Since that, only four additional epidemiological studies have investigated the 
association between SSRI and bleeding risk from the GIT. A systematic review 
published by Yuan et al. in 2006 (133) concluded that that there is very weak 
evidence to support a link between bleeding risk from GIT and SSRIs at a population 
level. However, the same review states that there is greater evidence to support that 
SSRIs may precipitate GIT bleeding under certain circumstances. The concurrent use 
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of SRIs and NSAIDs increase the bleeding risk markedly (8, 134). Similar conditions 
are reported in elderly patients (9). As the participants in our study were relative 
young (range: 21-54 years) and were asked specifically if they had ingested drugs 
know to interfere with platelet function, the possibility that SRI precipitate GIT 
bleeding in given conditions can not be excluded from our study.  
 
5.8 Tryptophan, tryptophan metabolites and serotonin 
In our study we observed no difference regarding tryptophan and some of the 
important tryptophan metabolites in plasma between the test and control group.  
We detected, however, a markedly decreased content of platelet serotonin for blood 
donors using SRI compared to blood donors without medication. This last finding is 
in line with many other published studies (14, 20, 135), and is probably related to 
decreased uptake of serotonin from serum. We aimed to investigate if decreased 
serotonin reuptake might mobilize tryptophan for the synthesis of serotonin and 
consequently deplete tryptophan stores and lower concentrations of metabolites in the 
kynurenine pathway. Our results indicate no such effect.  
The fact that we observed markedly decreased platelet serotonin in the test group, 
confirm that the individuals in the study was adherent to the treatment regimen.   
 
5.9 Limitations of the study 
The most obvious limitation in our study is the small sample size. Another limitation 
of the study is that not all available SRI on the Norwegian marked was included in the 
study. Interestingly, a nested case-control study published by Meijer et al. in 2004 
managed to show a moderate linear relationship between the risk of hospitalization 
because of bleeding and the affinity of the antidepressant on the SERT (136). In this 
study, fluoxetine, sertraline, and paroxetine were classified with high degree of 
inhibition of serotonin reuptake, while citalopram, venlafaxine and fluvoxamine were 
included in the class with intermediate affinity to SERT. Escitalopram was not 
included in the study. It must be taken into consideration that our study only included 
one of the drug (paroxetine) in the class with high degree of inhibition of serotonin 
transport reuptake.  
 
  59 
In our study, all individuals included in the test group had used a SRI for at least one 
year. None of the individuals used maximum doses of the drugs, except one, who 
used 20 mg escitalopram. The possible effect of dose and duration of treatment have 
been investigated by de Abajo et al. in 1999 (137). They found no evidence that these 
factors influenced the risk of upper gastrointestinal bleeding. However, there are 
studies that have observed in vitro dose-dependent inhibition on human platelets 
(137). 
 
According to the current guidelines, platelet concentrate may be stored for 7 days if 
there is control of possible bacterial contamination and for five days without such 
testing. Our results are limited to a storage period of 5 days.  
 
5.10 Conclusion 
The results from our pilot study indicate that individuals using SRIs do not have 
altered platelet function and can be accepted as platelet donors. Routine tests confirm 
high platelet quality during storage obtained from blood donors using SRIs. Our 
findings are limited to platelets stored for 5 days and for low doses of the drugs. There 
is a need for further studies to clearly identify the effect of SRI on platelet during 
storage. Our results also show that individuals using SRI have markedly lower platelet 
serotonin. 
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